Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Importantly, the combination of giredestrant and everolimus was well tolerated
Merck opens first climate-neutral manufacturing facility in Ireland
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Subscribe To Our Newsletter & Stay Updated